NCT02271009View on ClinicalTrials.gov

Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC

PHASE2CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Allergic Rhino-Conjunctivitis
Interventions
DRUG

AllerT

Ultrafast immunotherapy

DRUG

Placebo

placebo control

Trial Locations (1)

L4W 1A4

Inflamax Research Inc., Mississauga

Sponsors

Lead Sponsor

Anergis
All Listed Sponsors
collaborator

Inflamax Research Incorporated

INDUSTRY

lead

Anergis

INDUSTRY

NCT02271009 - Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC | Biotech Hunter | Biotech Hunter